Shanghai Haohai Biological Technology Co (HKSE:06826) Total Receivables: HK$494 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06826 Shanghai Haohai Biological Technology Co Ltd HKSE:06826
87 GF Score
Price HK$16.77
GF Value HK$27.61
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Shanghai Haohai Biological Technology Co Total Receivables?

Shanghai Haohai Biological Technology Co HKSE:06826 -0.24% 87 Total Receivables is HK$494 Mil as of Jun. 2026. GuruFocus rates HKSE:06826 with a GF Score™ of 87/100 and a GF Value™ of HK$27.61 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Shanghai Haohai Biological Technology Co's Total Receivables for the quarter that ended in Jun. 2026 was HK$494 Mil.

Shanghai Haohai Biological Technology Co Total Receivables Related Terms

Shanghai Haohai Biological Technology Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Shanghai Haohai Biological Technology Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Haohai Biological Technology Co Total Receivables Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 482.91 447.17 393.12 394.34 370.01

Shanghai Haohai Biological Technology Co Quarterly Data
Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Mar26 Jun26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 486.90 459.93 370.01 357.27 494.39
HKSE:06826
87GF Score
Shanghai Haohai Biological Technology Co Ltd HKSE:06826
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Haohai Biological Technology Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of HK$494 Mil mean?
Shanghai Haohai Biological Technology Co (HKSE:06826) has a Total Receivables of HK$494 Mil as of Jun. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Shanghai Haohai Biological Technology Co and its competitors.
Is Shanghai Haohai Biological Technology Co's Total Receivables too high?
Shanghai Haohai Biological Technology Co's current Total Receivables is HK$494 Mil. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's Total Receivables compare to VRTX and REGN?
Shanghai Haohai Biological Technology Co's Total Receivables of HK$494 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Shanghai Haohai Biological Technology Co and its competitors. Shanghai Haohai Biological Technology Co's current Total Receivables is HK$494 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (HKSE:06826) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$27.61, compared to a current price of HK$16.77 — trading 39.3% below its estimated fair value. The current Total Receivables is HK$494 Mil. Shanghai Haohai Biological Technology Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (HKSE:06826), the current Total Receivables is HK$494 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Haohai Biological Technology Co (HKSE:06826) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued. The current stock price of HK$16.77 is trading 39.3% below its estimated GF Value™ of HK$27.61. GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.

Key valuation signals for HKSE:06826:

  • Total Receivables: HK$494 Mil
  • GF Value™: HK$27.61 vs. price of HK$16.77 (39.3% below fair value)
  • GF Score™: 87/100 with 4 warning signs

No single metric tells the full story. See the HKSE:06826 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Haohai Biological Technology Co Business Description

Other Exchanges 5HB:Germany688366:China
Address No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
87GF Score

Get the complete analysis for HKSE:06826

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$16.77
Price
HK$27.61
GF Value